Iniciar sesión Regístrese gratis

Aisling Capital Management L.P. 13F annual report

Aisling Capital Management L.P. is an investment fund managing more than $231 billion ran by Robert Wenzel. There are currently 15 companies in Mr. Wenzel’s portfolio. The largest investments include Bridgebio Pharma Inc. (bbio) and Syndax Pharmaceuticals, Inc. (sndx), together worth $175 billion.

$231 billion Assets Under Management (AUM)

As of 1st August 2024, Aisling Capital Management L.P.’s top holding is 6,068,125 shares of Bridgebio Pharma Inc. (bbio) currently worth over $154 billion and making up 66.5% of the portfolio value. In addition, the fund holds 1,025,000 shares of Syndax Pharmaceuticals, Inc. (sndx) worth $21 billion. The third-largest holding is Verona Pharma Plc (vrna) worth $16.1 billion and the next is Elevation Oncology Inc (elev) worth $7.65 billion, with 2,834,910 shares owned.

Currently, Aisling Capital Management L.P.'s portfolio is worth at least $231 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Aisling Capital Management L.P.

The Aisling Capital Management L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Robert Wenzel serves as the Chief Financial Officer at Aisling Capital Management L.P..

Recent trades

In the most recent 13F filing, Aisling Capital Management L.P. revealed that it had opened a new position in Calcimedica, Inc. (calc) and bought 521,114 shares worth $2.06 billion.

On the other hand, there are companies that Aisling Capital Management L.P. is getting rid of from its portfolio. Aisling Capital Management L.P. closed its position in Spruce Biosciences, Inc. (sprb) on 8th August 2024. It sold the previously owned 1,205,511 shares for $2.72 billion.

One of the smallest hedge funds

The two most similar investment funds to Aisling Capital Management L.P. are Bank Ozk and Eukles Asset Management. They manage $231 billion and $231 billion respectively.


The complete list of Aisling Capital Management L.P. trades based on 13F SEC filings

These positions were updated on August 8th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Bridgebio Pharma Inc. (bbio)
No change
6,068,125
$153,705,606,000 66.52%
Syndax Pharmaceuticals, Inc. (sndx)
No change
1,025,000
$21,043,250,000 9.11%
Verona Pharma Plc (vrna)
No change
1,115,352
$16,127,990,000 6.98%
Elevation Oncology Inc (elev)
No change
2,834,910
$7,654,257,000 3.31%
Nuvation Bio Inc. (nuvb)
No change
2,541,009
$7,419,746,000 3.21%
Compass Pathways Plc (cmps)
No change
964,500
$5,825,580,000 2.52%
Monte Rosa Therapeutics Inc (glue)
No change
1,472,331
$5,506,518,000 2.38%
Biomea Fusion Inc (bmea)
No change
798,757
$3,594,407,000 1.56%
Poseida Therapeutics Inc. (pstx)
No change
1,043,267
$3,046,340,000 1.32%
Spruce Biosciences, Inc. (sprb)
Closed
1,205,511
$2,724,455,000
Calcimedica, Inc. (calc)
Opened
521,114
$2,063,611,000 0.89%
Marker Therapeutics, Inc. (mrkr)
No change
314,286
$1,706,571,000 0.74%
Avrobio, Inc. (avro)
Closed
1,009,779
$1,555,060,000
Tectonic Therapeutic Inc (tecx)
Opened
84,148
$1,385,918,000 0.60%
Reneo Pharmaceuticals Inc (rphm)
No change
886,075
$1,337,973,000 0.58%
Aeglea Biotherapeutics Inc (agle)
Closed
67,645
$828,652,000
Aclaris Therapeutics Inc (acrs)
No change
434,455
$477,901,000 0.21%
Viracta Therapeutics Inc (virx)
No change
288,571
$156,896,000 0.07%
Atreca Inc. (bcel)
Closed
387,653
$101,177,000
No transactions found
Showing first 500 out of 19 holdings

Hedge funds similar to Aisling Capital Management L.P.